Part, Chapter, Paragraph
1 I, 2. 10. 4 | The US based Centre for Medicines in the Public Interest predicts
2 I, 2. 10. 4 | unit of use of all licensed medicines products” using the GS1
3 II, 5. 5. 3 | There is no cure for MS, but medicines may slow it down and help
4 II, 5. 15.Acr | Medicinal Products~EMEA~European Medicines Evaluation Agency~ERCN~European
5 II, 5. 15. 4 | development and marketing of medicines to treat, prevent or diagnose
6 II, 5. 15. 4 | established at the European Medicines Agency (EMEA) to review
7 II, 5. 15. 4 | the intention to develop medicines for rare diseases. This
8 II, 5. 15. 6 | Orphan Diseases in “Priority Medicines for Europe and the World:
9 II, 6. 4. 3 | consultation with the European Medicines Agency.~ ~Furthermore, the
10 II, 7. 4. 6 | firearms, toxic gases, medicines, herbicides and pesticides),
11 II, 9 | This may be because many medicines can impair driving ability,
12 II, 9. 1. 2 | network by the European Medicines Agency is an important step
13 II, 9. 2. 5 | More than 50% of the medicines prescribed for children
14 II, 9. 2. 5 | development and authorisation of medicines for use in children.~ ~Policies~ ~
15 II, 9. 4. 3 | This may be because many medicines can impair driving ability,
16 II, 9. 4. 4 | This may be because many medicines can impair driving ability,
17 III, 10. 2. 1(14)| cases due to psychoactive medicines or non-overdose deaths,
18 III, 10. 2. 1 | and sometimes prescribed medicines in a potentially harmful
19 III, 10. 4. 2 | pesticides and veterinary medicines in food; additives, flavourings,
20 III, 10. 4. 2 | residues of veterinary medicines and contaminants in food
21 III, 10. 4. 2 | KAP, 2003~ ~Veterinary medicines~ ~ ~ ~ ~Antibacterial agents~
22 IV, 11.Acr | Panel Survey~EMEA~European Medicines Agency~HOPE~European Hospital
23 IV, 11. 1. 1 | advances in health care and medicines in particular, have witnessed
24 IV, 11. 1. 5 | effective and economic use of medicines in hospitals in accordance
25 IV, 11. 3 | access and accessibility of medicines.~ ~
26 IV, 11. 3. 2 | access to safe and effective medicines and control costs. On the
27 IV, 11. 3. 2 | development for new innovative medicines, and provide economic incentives
28 IV, 11. 3. 2 | authorization via the European Medicines Agency (EMEA), pricing and
29 IV, 11. 4 | Pharmaceuticals and biological medicines e.g. monoclonal antibody (
30 IV, 11. 6. 4 | Reimbursement Committee of the Medicines Agency in Italy), often
31 IV, 12. 1 | authorization via the European Medicines Agency (EMEA), pricing and
32 IV, 12. 4 | property rights and access to medicines; legal framework for public
33 IV, 12. 4 | consequences.~ ~EMEA~ ~European Medicines Agency (London, UK) - Established
34 IV, 12. 4 | evaluation and supervision of medicines, for the benefit of public
35 IV, 12. 4 | Enterprise and the European Medicines Agency (EMEA) on the development
36 IV, 12. 4 | on the evaluation of new medicines and the launch in 2006 of
37 IV, 12. 4 | safety, eHealth, Innovative Medicines Initiative, actions related
38 IV, 12. 8 | agencies, such as the European medicines Agency in London and the
39 IV, 12. 10 | are not only subject to Medicines Act and usual approval procedures (
40 IV, 12. 10 | of the refugees, in the Medicines sans Frontiers, etc. The
41 IV, 12. 10 | National Organization of Medicines (EOF) runs continually a
42 IV, 12. 10 | Decree Law 176/2007: New medicines Act, that transposes into
43 IV, 12. 10 | requirements for the dispensing of medicines for home delivery and through
44 IV, 12. 10 | allowing for over the counter medicines to be sold outside pharmacies (
45 IV, 12. 10 | the promotion of Generic Medicines (2004&2007);~- Campaign
46 IV, 12. 10 | 2004&2007);~- Campaign on medicines and driving (2004).~Environment
